ASTRO 2017: Highlights in Advanced Lung Cancer

Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

This video highlights studies on advanced lung cancer with practice-changing potential presented at the 2017 ASTRO Annual Meeting.

In this video, Maria Werner-Wasik, MD, of Thomas Jefferson University Hospital in Philadelphia, discusses selected studies on the treatment of lung cancer presented at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.

Werner-Wasik was the discussant for a session on lung cancer that featured the following abstracts, which were selected for their importance and practice-changing potential:

• Abstract 223: Quality of life (QOL) outcomes in a phase III randomized trial of optimization of treatment of advanced non–small-cell lung cancer using radiotherapy and chemotherapy: IAEA multicentric randomized phase III study (NCT00864331)

• Abstract LBA-3: Consolidative radiotherapy for limited metastatic non–small-cell lung cancer (NSCLC): a randomized phase II trial

• Abstract LBA-4: PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC

• Abstract 227: Long-term results of RTOG 0617; a randomized phase III comparison of standard dose vs high-dose conformal chemoradiotherapy +/- cetuximab for stage III non–small-cell lung cancer

• Abstract 33: Long-term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase II study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non–small-cell lung cancer

Recent Videos
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
Related Content
Data from the DeLLphi-304 trial support the full approval of tarlatamab in this extensive-stage small cell lung cancer population.

Tarlatamab Earns Traditional FDA Approval in ES-SCLC

Russ Conroy
November 19th 2025
Article

Data from the DeLLphi-304 trial support the full approval of tarlatamab in this extensive-stage small cell lung cancer population.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Data from a phase 1a/1b trial show that no patients discontinued STK-012 due to treatment-related adverse effects.

Novel IL-2 Therapy Combo Yields Initial Responses in Nonsquamous NSCLC

Russ Conroy
November 8th 2025
Article

Data from a phase 1a/1b trial show that no patients discontinued STK-012 due to treatment-related adverse effects.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC

Russ Conroy
November 4th 2025
Article

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.

HER3-DXd Yields Activity in NSCLC, Breast Cancer Brain Metastasis Groups

Russ Conroy
October 31st 2025
Article

Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.